Details

Published: 22 April 2026

Hits: 12

A groundbreaking study published in the May 2026 issue of Anesthesiology has raised serious concerns about naloxone overdose reversal when potent synthetic opioids are involved. Researchers found that one standard dose may not be enough to fully protect a person in crisis. The findings carry urgent implications for anyone on the front lines of the ongoing drug crisis.

Dr Maarten A. van Lemmen of Leiden University Medical Center in the Netherlands led the research. His team tested a single 4mg intranasal dose of Narcan against respiratory depression triggered by fentanyl and sufentanil. Both are synthetic opioids with an exceptionally strong grip on the brain’s opioid receptors.

What the Study Found About Naloxone Overdose Reversal

The trial involved 30 participants split into two groups. Twelve had never used opioids and 18 reported using opioids every day. Researchers gave each person a continuous infusion of either fentanyl or sufentanil, enough to reduce breathing by 30 to 40 per cent, before administering intranasal naloxone.

The results painted a troubling picture. Narcan restored normal breathing rates within two to four minutes across all participants. However, carbon dioxide levels recovered far more slowly, taking between 11 and 17 minutes on average. That gap matters because carbon dioxide clearance reflects whether the lungs are actually working properly.

The picture grew more concerning with sufentanil, a drug roughly ten times more potent than fentanyl. Carbon dioxide levels never fully returned to normal in a significant proportion of subjects. Only 8 of 12 opioid-naive individuals showed complete recovery. Among daily opioid users, 10 of 12 recovered fully.

“Delayed and sometimes incomplete recovery of end-tidal carbon dioxide, particularly during exposure to the high-affinity opioid sufentanil, indicates reversal inefficacy and persistence of respiratory instability,” the authors concluded.

The Gap Between Looking Awake and Being Safe

One of the most striking findings concerns how a person looks after receiving naloxone versus how their body is actually functioning. A person can appear alert and responsive long before their breathing stabilises. An accompanying editorial by James P. Rathmell, editor-in-chief of Anesthesiology and Professor of Anaesthesia at Harvard Medical School, flagged this as a serious safety risk.

“This distinction has immediate implications for patient safety, observation practices, and dosing strategies,” Dr Rathmell and co-author Steven E. Kern wrote. They explained that re-sedation and delayed respiratory instability can still occur even after intranasal naloxone administration.

Someone who appears to have woken up may still be in serious danger. This is especially true with very high-affinity synthetic opioids like sufentanil and, by extension, carfentanil, which binds to receptors even more tightly.

The Scale of the Crisis and Why Naloxone Overdose Reversal Is Harder Now

Synthetic opioids now dominate the overdose landscape. Fentanyl and related drugs account for an estimated 60 to 79 per cent of overdose deaths in the United States. Over the past two decades, roughly 800,000 Americans have died from drug overdoses, the vast majority involving potent opioids. Their molecular grip on opioid receptors makes the standard naloxone overdose reversal protocol increasingly inadequate.

The study also recorded a phenomenon known as renarcotisation. After the initial reversal, breathing rate, carbon dioxide levels, and pupil size all drifted back towards opioid-suppressed levels as naloxone wore off. A single dose simply does not last long enough when a potent opioid remains in the system.

Naloxone Overdose Reversal and Withdrawal: Another Layer of Risk

Among the 18 daily opioid users in the trial, nine experienced withdrawal symptoms after receiving naloxone. Symptoms ranged from agitation and nausea to hypertension and vomiting. Seven participants withdrew from the study because of this. For people who use opioids regularly, the reversal process can itself become a crisis.

Symptoms typically started around 20 minutes after naloxone administration and peaked at roughly 30 minutes. All resolved within two hours. Still, this reaction creates real challenges for emergency responders working in unpredictable settings.

What This Means for Overdose Response

The study’s authors are direct on what practitioners should take away. A single naloxone dose cannot reliably reverse overdoses involving high-affinity synthetic opioids. Calling emergency services immediately remains essential, even when the drug appears to have worked. Multiple doses may be necessary. Close monitoring must continue long after the person regains consciousness.

Current overdose response guidelines developed around heroin, which binds to receptors far less powerfully than fentanyl. The drug supply has shifted dramatically. Those protocols now need urgent revision.

“Further studies are needed to address optimal naloxone doses and alternative formulations to address high-dose potent opioid threats,” the research team noted.

A Call for Updated Thinking on Intranasal Naloxone

The study does carry limitations. Laboratory infusions differ from real-world overdoses, where opioid levels spike then fall naturally. That natural decline may assist recovery in ways the experiment could not replicate. The level of respiratory depression induced, 30 to 40 per cent below baseline, was also moderate. Real overdoses often involve complete cessation of breathing, making a single intranasal naloxone dose even less likely to suffice.

A separate study by the same team found that when fentanyl caused full apnea, patients needed two to four Narcan doses to restore normal breathing. Together, the findings confirm that naloxone overdose reversal is not a one-and-done solution against today’s synthetic drugs.

Naloxone saves lives. But it is not a guarantee, and it was never a substitute for emergency medical care. Knowing its limits and acting on that knowledge could be the difference between survival and tragedy.

(Source: WRD News)

Details

Published: 09 April 2026

Hits: 67

Young people struggling with youth drug treatment needs have long been underserved by a system built around adults. That is now changing. The American Society of Addiction Medicine (ASAM) has published a landmark framework dedicated entirely to substance use disorder care for adolescents and young adults under 25, separating their standards from adult guidance for the first time.

The new volume, titled the Adolescent and Transition-Aged Youth edition of The ASAM Criteria, sets out the full range of services that should be available to every young patient. Previously, adolescent addiction treatment standards sat buried within adult-focused criteria, a setup that many clinicians had criticised for years.

Brain development continues well into a person’s mid-twenties. That biological reality shapes the entire framework. Young people are not simply smaller adults, and the risks they face from substance use reflect that difference.

Why Youth Drug Treatment Needs Its Own Framework

The numbers make a sobering case. Around 80% of adults living with substance use disorder started using substances before the age of 18. Those who begin before 15 are 6.5 times more likely to develop a dependency than those who wait until 21 or older. Early exposure does not just raise risk. It can reshape development, delay the acquisition of life skills, and set a difficult course for decades to come.

“Ongoing brain development during these formative years puts youth at a greater risk of developing the disease of addiction, which can lead to poor health outcomes and delayed life skill development,” said Dr Corey Waller, editor-in-chief of the new volume.

The ASAM now recommends early intervention for any young person already using substances and showing signs of rapid escalation. Waiting for a formal diagnosis before acting is no longer the preferred approach.

Adolescent Addiction Treatment: A Holistic, Family-Centred Model

The updated standards place the young person firmly at the centre, but they also widen the lens considerably. The framework promotes a model that brings in mental health services, connects with schools and community networks, and treats prevention as seriously as treatment itself.

This matters because youth drug treatment challenges rarely travel alone. Most adolescents dealing with substance-related difficulties also carry co-occurring mental health conditions. The new guidance pushes clinicians to address both at the same time, not in sequence.

The continuum of care expands too. New service levels include ongoing remission monitoring and integrated withdrawal management within youth-specific programmes. These are areas that existing guidance had largely overlooked.

Rising Risks Make the Case for Change

The clinical picture for young people has grown more complex in recent years. Fentanyl and other high-potency substances now reach adolescents far more readily than before. Clinicians report encountering levels of risk in young patients that would have been uncommon a decade ago.

“While there will be challenges to overcome to make this vision a reality, we must commit to building systems and payment models capable of delivering effective interventions and treatments for all young people who need them,” said Dr Waller.

Putting the New Standards Into Practice

ASAM presented the new criteria on 25 March at the Joint Meeting on Youth Prevention, Treatment, and Recovery. The Hazelden Betty Ford Foundation published the complete volume online and will release a print edition in June.

The Foundation also built a digital interface to help clinicians across the full care team put adolescent addiction treatment into practice without friction.

“The ASAM Criteria’s new adolescent treatment standards represent a tremendous opportunity to further elevate and individualise care for our nation’s children and young adults,” said Dr Joseph Lee, president and chief executive of the Hazelden Betty Ford Foundation.

The framework asks more than clinicians to act. It calls on commissioners, policymakers and system leaders to fund and build the infrastructure these standards require. With the evidence pointing clearly to adolescence as the window where intervention matters most, getting that infrastructure right carries consequences that stretch well beyond the clinic.

(Source: WRD News)

Details

Published: 01 April 2026

Hits: 186

The choices you make in your twenties may feel a world away from who you will be at 65. But a landmark new study from the University of Michigan suggests the brain keeps a much longer record than most of us realise. Researchers found that young adult substance use, including binge drinking, frequent cannabis use, and daily cigarette smoking between the ages of 18 and 30, links significantly to poorer self-reported memory in midlife, between the ages of 50 and 65.

The findings appear in the Journal of Aging and Health. The National Institute on Drug Abuse funded the work, making it one of the first studies to track these patterns across multiple decades of a person’s life.

A Study Decades in the Making

The research drew on data from the Monitoring the Future Longitudinal Panel Study. It followed participants from age 18, as far back as 1976, through to their mid-sixties. This long view let researchers see not just what people did in their youth, but what those habits ultimately cost them.

“Substance use has both acute and long-term effects on health and well-being,” said Megan Patrick, research professor at the Institute for Social Research. “Poor memory is a common sign of early dementia. We examined whether young adult substance use links to poor memory decades later in midlife.”

The study spanned nearly five decades. It captured real behavioural patterns across generations of young Americans, giving its conclusions real weight.

How Young Adult Substance Use Damages the Brain: Two Different Pathways

Not all substances damage the brain in the same way. The team identified a “triple threat”: binge drinking, near-daily cannabis use, and daily cigarette smoking in young adulthood. All three connect to memory problems in later life, but through entirely different mechanisms.

Cigarettes: the direct threat

Daily smoking between 18 and 30 predicted poorer memory in early midlife. Crucially, this held true even for people who stopped smoking by age 35. Quitting later in life does not appear to undo what cigarettes do to the developing brain during young adulthood.

Young brains are still forming during this period. Cigarette toxins appear to leave a mark that persists for decades, regardless of what happens afterwards.

Alcohol and cannabis: the addiction route

For binge drinking and frequent cannabis use, the picture differs. Heavy substance use in young adulthood does not directly cause memory loss thirty years later. Instead, it raises the likelihood of developing a Substance Use Disorder (SUD) in the thirties. That ongoing disorder then drives poorer cognitive functioning later in life.

This distinction matters enormously. For alcohol and cannabis, the window for intervention does not close at 30. Treating a substance use disorder in midlife could still help protect the brain.

“Even if someone thinks their current substance use may not be problematic because they don’t see it as affecting their health right now, there are still potential longer-term consequences to consider,” Patrick said.

What the Numbers Say About Heavy Substance Use in Young Adulthood

Self-reported poor memory is an early marker of cognitive decline and, in some cases, an early sign of dementia. Dementia now affects an estimated 55 million people worldwide, according to the World Health Organisation. That figure could reach 139 million by 2050, making early-life risk factors a pressing public health concern.

The study found that all three forms of heavy substance use in young adulthood directly associated with higher odds of poor self-rated memory in late midlife. For alcohol and cannabis, substance use disorder symptoms in early midlife fully explained those associations. For pack-a-day or heavier cigarette smoking, no such explanation applied, pointing to direct neurological damage instead.

Why Young Adult Substance Use Puts the Developing Brain at Risk

The brain does not finish developing until the mid-twenties. The prefrontal cortex, the region that handles decision-making, emotional regulation, and memory formation, is among the last areas to mature. Young adulthood is therefore a period of heightened neurological sensitivity.

“Young adulthood is a critical period for brain development,” Patrick noted. “Substance use patterns established during this period may have lasting consequences on memory and cognitive health much later in life.”

Heavy substance use in young adulthood is not simply a lifestyle choice with short-term effects. The evidence suggests it may reshape the trajectory of cognitive ageing for decades.

What This Means If You Smoked or Drank Heavily in Your Twenties

For those who smoked daily in their youth and have since quit, the findings may feel alarming. Giving up cigarettes by 35 does not appear to cancel the earlier neurological impact. Even so, cognitive decline is not inevitable. Staying proactive about brain health matters more than ever: regular exercise, good sleep, mental stimulation, and avoiding further substance use all help.

For those who drank heavily or used cannabis often in their twenties, the outlook is more actionable. Memory decline in this group links to ongoing substance use disorders rather than past behaviour alone. Getting appropriate support and treatment in midlife remains a meaningful step worth taking.

“Understanding these risk factors and their trajectory across the lifespan will inform strategies to support cognitive health,” Patrick said.

The Case for Early Intervention Against Young Adult Substance Use

Early action works far better than trying to reverse damage later. Identifying and addressing substance use in young people, before patterns become entrenched and neurological costs accumulate, gives the brain its best chance.

“This study demonstrates potential long-term detrimental impacts of young adult heavy substance use on cognitive health later in life,” Patrick said. “It highlights the importance of early interventions.”

For public health, the implications are clear. Prevention and support programmes targeting young people protect far more than immediate wellbeing. They may be among the most powerful tools available for safeguarding a generation’s long-term cognitive health.

The study was published in the Journal of Aging and Health. Authors: Megan E. Patrick, Yuk C. Pang, Yvonne M. Terry-McElrath, and Joy Bohyun Jang, University of Michigan Institute for Social Research.

(Source: WRD News)

Details

Published: 01 April 2026

Hits: 70

Violence is one of the most underreported issues facing women who use drugs. A major study published in JAMA Network Open in March 2026 shed new light on how widespread and serious this problem is, and why so many women suffer in silence.

The findings are deeply concerning. Yet understanding them is an important step towards building a society that truly protects its most vulnerable members.

What the Research Found About Violence Against Women Who Use Drugs

The study followed 431 women in Melbourne, Australia, over more than a decade. Researchers combined survey responses with hospital, ambulance, and emergency department records. The results paint a stark picture.

By the end of the study period, 82% of women had experienced at least one assault. A further 38% had experienced at least one sexual assault. These rates are roughly double those in the general female population, where around 39% report lifetime violence and 22% report sexual violence.

Almost one in four women (23%) attended an emergency department because of assault. One in five (19%) ended up in hospital. Ambulance callouts for assault reached 17% of the cohort.

Violence was not only common but recurring. At follow-up interviews, 59% of women reported being assaulted since their last interview, roughly within the previous 12 months. The median number of lifetime assaults was five, though many women reported far higher numbers.

Who Was Carrying Out the Violence?

Perpetrators went well beyond intimate partners. Whilst 53% of women named a partner as an assailant, nearly half (43%) also reported attacks by a stranger. That proportion is considerably higher than in the wider population. Friends or other family members were named by 39% of women. Drug dealers or other people who use drugs featured for 30%.

This range of perpetrators matters. Most support services focus on domestic and family violence. When assault also comes from strangers or people connected to drug environments, the gap in available support becomes very clear.

Assault and Drug Use in Women: The Barrier of Stigma

Despite how often violence occurred, only around one in three women sought health care after an assault. That figure alone tells us something has gone seriously wrong.

Qualitative interviews with ten women revealed why so many stay silent. Stigma came up repeatedly. Women felt judged or dismissed by healthcare providers the moment staff learned about their drug use, even when that use was years in the past.

One woman in her 50s put it plainly: some doctors “don’t want to know you” once they discover a history of drug use, regardless of how long ago it was.

Retelling a complex and painful history to every new clinician is exhausting. For women carrying trauma, that prospect alone can stop them from seeking help.

Fear of Losing Children

Fear of child protection involvement stood out as one of the biggest barriers. Several women stayed silent about violence because they feared that speaking up would lead to their children being removed.

Sara described being “too scared” to reach out. She believed she would have opened up had she found someone she trusted, someone who would not immediately involve child protection services.

The numbers tell a similar story. Women with a history of child removal were more than twice as likely to seek health care after assault. Women who reported sexual assault had four times the odds of seeking help. Severity clearly pushes some women to act. But for many others, fear continues to win.

Violence Against Women Who Use Drugs: Practical Obstacles Matter Too

The barriers around assault and drug use in women are not only emotional. Practical challenges block access just as effectively.

Some women could not attend services because they had no transport. Others lacked phone credit to call helplines. Many services required a phone call just to book an appointment, an immediate obstacle for anyone without a working phone.

Eve had been in multiple abusive relationships and never once accessed support. She named transport costs and phone credit among her reasons. She also pointed out that even when a service offered a free number to ring, finding a payphone that could make the call was its own challenge.

The Difference a Trusted Clinician Can Make

The research also captured something genuinely hopeful. When women found a clinician they trusted, that relationship changed everything.

Jane described a maternal child health nurse who noticed signs of abuse across several visits. The nurse reached out consistently, and when the time came, helped Jane access refuge housing with all four of her children. Jane said the team made her feel completely safe and supported her through the whole process.

Mira credited her prescriber with helping her leave an abusive relationship. He asked about her safety at every visit and offered to document her injuries. That steady, non-judgemental concern gave her the confidence to walk away.

Individual clinicians can make an enormous difference. Relationship-based care matters deeply for this group of women.

What This Means for Policy and Prevention

The study’s authors called for women who use drugs to gain formal recognition in Australia’s National Plan to End Violence Against Women and Children. That plan currently acknowledges elevated risk for Aboriginal and Torres Strait Islander women, culturally and linguistically diverse women, LGBTQIA+ people, and women with disabilities. It does not name women who use drugs.

That gap needs addressing. Violence against women who use drugs occurs at rates that exceed even other marginalised groups already recognised in policy. Without targeted support, this population stays excluded from the systems designed to help them.

Violence and substance use are deeply connected. Services need to reflect that reality. Women-centric models, built on trust and staffed by people with relevant lived experience, offer a stronger path forward than approaches that inadvertently penalise women for their circumstances.

Conclusion

Violence is pervasive in the lives of women who use drugs, it is severe, and the systems meant to help them are missing them. Women do not stay silent because they want to. Stigma, fear, and practical barriers push them away. The research community has now documented this clearly. The next step belongs to policymakers, services, and clinicians who have the power to respond.

Recognising this burden is not just a research priority. It is a moral one.

(Source: JAMAnetwork)